{"product_id":"rdhl-vrio-analysis","title":"RedHill Biopharma Ltd. (RDHL): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to RedHill Biopharma Ltd. (RDHL)'s market dominance by diving into this essential VRIO Analysis. We rigorously test whether its core assets are truly Valuable, Rare, Inimitable, and Organized enough to secure a lasting competitive advantage. Discover the distilled summary of its strengths and weaknesses - the key to its future performance - by reading on below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eRedHill Biopharma Ltd. (RDHL) - VRIO Analysis: Talicia U.S. Commercial Infrastructure \u0026amp; Market Position\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core revenue engine for RedHill Biopharma Ltd. (RDHL) right now, and it all centers on Talicia in the U.S. market. The immediate takeaway is this: the commercial setup is currently generating real cash flow, but the structure supporting it is actively changing, which shifts the long-term outlook.\u003c\/p\u003e\n\n\u003cp\u003eHere is the quick math on the current state of the Talicia commercial footprint as of the first half of 2025.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n      \u003ctd\u003eAssessment\u003c\/td\u003e\n      \u003ctd\u003eKey Metric\/Finding (H1 2025 Data)\u003c\/td\u003e\n    \u003c\/tr\u003e\n  \u003c\/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003ctd\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/td\u003e\n      \u003ctd\u003eYes\u003c\/td\u003e\n      \u003ctd\u003eU.S. Net Revenues: \u003cstrong\u003e$3.3 million\u003c\/strong\u003e; Covered Lives: \u003cstrong\u003e\u0026gt;204 million\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/td\u003e\n      \u003ctd\u003eYes\u003c\/td\u003e\n      \u003ctd\u003eNo. 1 branded H. pylori therapy prescribed by U.S. gastroenterologists.\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003e\u003cstrong\u003eInimitability\u003c\/strong\u003e\u003c\/td\u003e\n      \u003ctd\u003eDifficult (Costly\/Time-Consuming)\u003c\/td\u003e\n      \u003ctd\u003eBrand recognition and established formulary access are barriers to entry.\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/td\u003e\n      \u003ctd\u003eChanging (Recently Restructured)\u003c\/td\u003e\n      \u003ctd\u003eAchieved revenue growth with a significantly leaner team structure in H1 2025.\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/td\u003e\n      \u003ctd\u003eTemporary\u003c\/td\u003e\n      \u003ctd\u003eStrong current position, but dependent on pipeline success to sustain long-term.\u003c\/td\u003e\n    \u003c\/tr\u003e\n  \u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eValue: Driving Current Top-Line Performance\u003c\/h\u003e\n\u003cp\u003eThe U.S. commercial infrastructure for Talicia is definitely valuable because it is the primary source of current revenue. For the first half of 2025, this asset generated $3.3 million in U.S. net revenues. That revenue is supported by securing access for over 204 million covered lives, which is a massive footprint in the U.S. healthcare system. This access means the product gets seen and prescribed by the right doctors, which is the whole point of a commercial team.\u003c\/p\u003e\n\n\u003ch\u003eRarity: The Niche Market Leader\u003c\/h\u003e\n\u003cp\u003eIt is rare to have the clear market leader in a specific, FDA-approved niche like this. Talicia is cited as the number one branded H. pylori therapy prescribed by U.S. gastroenterologists. That position is not accidental; it reflects years of focused promotion and the drug’s profile as the only FDA-approved, all-in-one, low-dose rifabutin-based therapy addressing resistance. That specific combination and market perception are hard to replicate overnight.\u003c\/p\u003e\n\n\u003ch\u003eImitability: The Cost of Catching Up\u003c\/h\u003e\n\u003cp\u003eHonestly, imitation is possible, but it is not cheap or fast. Competitors can certainly launch new entrants, but they face two major hurdles: brand recognition and formulary status. Overcoming the established perception among gastroenterologists - especially given Talicia is listed as a first-line option in the American College of Gastroenterology Clinical Guidelines - takes significant time and marketing spend. The patent protection through 2042 plus the eight years of QIDP exclusivity also raise the imitation cost substantially.\u003c\/p\u003e\n\n\u003ch\u003eOrganization: The Cumberland Partnership Shift\u003c\/h\u003e\n\u003cp\u003eThis is where things get interesting for the near term. The organization was clearly efficient in H1 2025, showing increased revenues with significantly reduced resources - a testament to the leaner structure implemented earlier. However, the late 2025 strategic partnership with Cumberland Pharmaceuticals, where they invested $4 million for a 30% stake and entered a co-commercialization agreement, fundamentally changes the organization. Now, operational responsibility and net revenues are shared equally in the U.S. This new structure aims to boost sales growth by leveraging Cumberland’s national sales force, but it also means RedHill Biopharma Ltd. is now sharing the upside and the operational control of its primary asset.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage: Temporary Status Quo\u003c\/h\u003e\n\u003cp\u003eGiven the current structure, the advantage is best classified as \u003cstrong\u003eTemporary\u003c\/strong\u003e. The market position is currently strong, supported by the $3.3 million in H1 2025 U.S. revenue and the No. 1 prescription ranking. But, without successful pipeline advancements - like RHB-204 or opaganib - to provide the next major revenue stream, this advantage will erode as competitors aggressively target the $H. pylori$ space. The new partnership is a financial stabilizer, but it shares the commercial upside, preventing a sustained advantage unless the pipeline delivers.\u003c\/p\u003e\n\n\u003cp\u003eFinance: draft the pro-forma H2 2025 cash flow incorporating the Cumberland revenue share by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eRedHill Biopharma Ltd. (RDHL) - VRIO Analysis: RHB-204 Crohn's Disease Clinical Program\n\u003c\/h2\u003e\n\n\u003ch\u003eValue: Offers a potential paradigm shift in treatment by targeting a defined MAP-positive patient population, which could lead to a high-value asset.\u003c\/h\u003e\n\u003cp\u003eThe Crohn's disease market in the U.S., Japan, and five major European markets is forecast to expand from $13.6 billion in 2024 to over $19 billion in 2033. RHB-204 is designed to treat the suspected root cause, Mycobacterium avium subspecies paratuberculosis (MAP), in susceptible patients, potentially treating both the cause and symptoms. Up to 40% of Crohn's Disease (CD) patients fail to respond to anti-TNF treatment, indicating a significant unmet need for an alternative oral therapy.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFeature\u003c\/th\u003e\n\u003cth\u003eRHB-104 Phase 3 Data\u003c\/th\u003e\n\u003cth\u003eRHB-204 Crohn's Disease Program\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEfficacy Improvement vs SoC\u003c\/td\u003e\n\u003ctd\u003eStatistically significant 64% improvement.\u003c\/td\u003e\n\u003ctd\u003ePotential paradigm shift by targeting MAP.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget Population\u003c\/td\u003e\n\u003ctd\u003eAll-comer CD patients.\u003c\/td\u003e\n\u003ctd\u003eSpecifically defined MAP-positive CD patients.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormulation Improvement\u003c\/td\u003e\n\u003ctd\u003eBaseline.\u003c\/td\u003e\n\u003ctd\u003e40% pill burden reduction.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent Protection End\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eAt least through 2041.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eRarity: Being the first to run a clinical study in a wholly MAP-positive Crohn's disease population is scientifically unique right now.\u003c\/h\u003e\n\u003cp\u003eThe planned novel Phase 2 RHB-204 study is set to be the first ever clinical trial in Crohn's disease to test a specifically defined MAP-positive CD patient population. The study will utilize novel endpoints including mucosal healing (considered the FDA's new gold standard) correlated with MAP eradication.\u003c\/p\u003e\n\n\u003ch\u003eImitability: The specific clinical trial design and the scientific insight into the MAP-positive subset are difficult to replicate without similar foundational research.\u003c\/h\u003e\n\u003cp\u003eThe program builds upon positive safety and efficacy results from the predecessor RHB-104 Phase 3 study. The innovative design, enabled by collaborations with academic centers for cutting-edge MAP detection diagnostics, allows for a smaller sample size, which translates to lower study costs and faster time to completion. Research and Development Expenses for the first half of 2025 were $1 million.\u003c\/p\u003e\n\n\u003ch\u003eOrganization: Management has secured positive FDA feedback on the pathway to approval, showing they can effectively navigate regulatory strategy.\u003c\/h\u003e\n\u003cp\u003eRedHill announced positive FDA feedback following a Type C meeting regarding the pathway to approval for RHB-204. The Company plans to fund the groundbreaking program through expected non-dilutive financing, with a grant application submitted and discussions ongoing. Net Cash Used in Operating Activities for the first half of 2025 was $5 million.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage: Sustained. If successful, the first-mover advantage in this specific patient segment will be protected by strong IP and regulatory hurdles.\u003c\/h\u003e\n\u003cp\u003eRHB-204 is protected by patents until at least 2041. Potential regulatory advantages that could confer sustained exclusivity include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFDA Fast Track designation (already granted for NTM disease).\u003c\/li\u003e\n\u003cli\u003eExpected transferal of pediatric orphan drug designation.\u003c\/li\u003e\n\u003cli\u003ePotential for breakthrough therapy designation.\u003c\/li\u003e\n\u003cli\u003ePotential for additional regulatory exclusivity and a priority review voucher.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eRedHill Biopharma Ltd. (RDHL) - VRIO Analysis: RHB-102 Out-Licensing Agreement with Hyloris Pharma\n\u003c\/h2\u003e\n\n\u003ch\u003e\u003ch\u003eValue: Provides non-dilutive funding and validation, securing an up to $60 million deal for ex-North America rights.\u003c\/h\u003e\n\u003cp\u003eThe agreement secures an upfront payment and up to $60 million in potential milestone payments contingent upon achieving specified commercial targets for RHB-102 outside the US, Canada, and Mexico. Royalties are structured up to the mid-20s percent on revenues, with minimum annual payments to RedHill. The asset, RHB-102, is a once-daily, proprietary, bimodal extended-release oral tablet formulation of ondansetron, available in 12mg and 24mg dose strengths.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eRarity: Securing a significant out-license for a late-stage asset is rare for a company of this size, especially while retaining key markets.\u003c\/h\u003e\n\u003cp\u003eThe deal, announced on February 25 or 26, 2025, involves exclusive rights outside North America, allowing RedHill to continue development for US Food and Drug Administration (FDA) approval. At the time of the announcement, RedHill's Current Market Cap was $6.14M and YTD Price Performance was -24.69%. The global antiemetics drugs market size was valued at approximately $7.5 billion in 2023.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eImitability: The deal terms and the specific partnership are unique, but the underlying asset (RHB-102) could be licensed by others.\u003c\/h\u003e\n\u003cp\u003eThe specific combination of upfront payment, up to $60 million in milestones, and up to mid-20s percent royalties is unique to this partnership. RHB-102 is in advanced development for oncology support, acute gastroenteritis, gastritis, and diarrhoea-predominant irritable bowel syndrome (IBS-D). Positive results from the US Phase 2 IBS-D study (12 mg dose) and Phase 3 GUARD gastroenteritis study (24 mg dose) were published in The American Journal of Gastroenterology and JAMA Network Open, respectively.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization: The company successfully executed this major transaction, demonstrating capability in deal-making to fund development.\u003c\/h\u003e\n\u003cp\u003eThe execution of the Hyloris agreement, alongside other financial highlights such as an approximately $8 million plus legal costs NY Supreme Court summary judgment win against Kukbo, demonstrates organizational capability. The Average Trading Volume for RDHL was 14,257 around the announcement date. The company is advancing RHB-204 in the $12 billion Crohn's disease space.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage: Temporary. The upfront\/minimum payments provide immediate cash, but the long-term value depends on Hyloris’s execution.\u003c\/h\u003e\n\u003cp\u003eThe immediate financial benefit is the upfront payment and minimum annual payments, providing non-dilutive funding. The potential total value is up to $60 million in milestones plus royalties. The market context suggests growth, with the global antiemetics market expected to grow at a CAGR of approximately 6% from 2024 to 2030.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRHB-102 Out-Licensing Deal Summary Metrics\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eTerritory\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Potential Deal Value (Milestones)\u003c\/td\u003e\n\u003ctd\u003eUp to $60 million\u003c\/td\u003e\n\u003ctd\u003eEx-North America Rights\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalty Rate\u003c\/td\u003e\n\u003ctd\u003eUp to mid-20s percent\u003c\/td\u003e\n\u003ctd\u003eOn Revenues\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Payment\u003c\/td\u003e\n\u003ctd\u003eUndisclosed amount\u003c\/td\u003e\n\u003ctd\u003eReceived by RedHill\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMinimum Payments\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eAnnual Payments to RedHill\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensed Territory Exclusions\u003c\/td\u003e\n\u003ctd\u003eUS, Canada, Mexico\u003c\/td\u003e\n\u003ctd\u003eNorth America Retained by RedHill\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsset Dose Strengths\u003c\/td\u003e\n\u003ctd\u003e12mg and 24mg\u003c\/td\u003e\n\u003ctd\u003eRHB-102 Formulation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Antiemetics Market CAGR (2024-2030)\u003c\/td\u003e\n\u003ctd\u003eApproximately 6%\u003c\/td\u003e\n\u003ctd\u003eMarket Growth Projection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Antiemetics Market Size (2023)\u003c\/td\u003e\n\u003ctd\u003eApproximately $7.5 billion\u003c\/td\u003e\n\u003ctd\u003eMarket Valuation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eRedHill Biopharma Ltd. (RDHL) - VRIO Analysis: Opaganib Development Assets (Prostate Cancer\/GI-ARS)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Diversifies the pipeline into oncology (Phase 2 with Bayer) and addresses a critical need in GI-Acute Radiation Syndrome (GI-ARS) via U.S. government funding.\u003c\/p\u003e\n\u003cp\u003eThe asset benefits from a further \u003cstrong\u003e$1.7 million\u003c\/strong\u003e in U.S. Government funding via a Small Business Innovation Research (SBIR) grant to its partner Apogee for GI-ARS development, which is complementary to a 'multimillion dollar-valued' U.S. Government Radiation and Nuclear Countermeasures Program (RNCP) product pipeline development contract.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The ongoing, U.S. Government-funded work for GI-ARS protection is a specialized, non-dilutive resource.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe GI-ARS development follows confirmation of the Animal Rule regulatory pathway applicability from the FDA.\u003c\/li\u003e\n\u003cli\u003eThe asset is supported by multiple U.S. Government grants, including the \u003cstrong\u003e$1.7 million\u003c\/strong\u003e SBIR grant.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The existing collaborations and data from government-funded programs are hard for a competitor to build from scratch.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Recruitment is underway for the Bayer-supported Phase 2 study, showing active management of this collaboration.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Phase 2 study in metastatic castrate-resistant prostate cancer (mCRPC) is designed to enroll 60 participants randomized on a 1:1 ratio.\u003c\/li\u003e\n\u003cli\u003eThe study utilizes the PCPro™ lipid biomarker test to identify patients with poor prognosis.\u003c\/li\u003e\n\u003cli\u003eThe trial is registered on clinicaltrials.gov as NCT04207255.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The Bayer partnership is a strong signal, but the asset needs to show clinical efficacy to secure sustained advantage.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eIndication\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSBIR Grant Funding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGI-ARS Development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRNCP Contract Value\u003c\/td\u003e\n\u003ctd\u003eMultimillion Dollar-Valued\u003c\/td\u003e\n\u003ctd\u003eGI-ARS Development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2 Trial Size (Opaganib\/Darolutamide)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e60\u003c\/strong\u003e participants\u003c\/td\u003e\n\u003ctd\u003eProstate Cancer (mCRPC)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProstate Cancer Annual Cases\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e1.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eGlobal Burden\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProstate Cancer Market Value (2023)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$12 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eGlobal Market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRedHill Current Revenue (as of Feb 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.71 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eContextual Financial Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eRedHill Biopharma Ltd. (RDHL) - VRIO Analysis: Streamlined Operational Cost Structure (Post-Overhaul Efficiency)\n\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eDrastically improved the financial runway; Operating Loss fell to \u003cstrong\u003e$4.4 million\u003c\/strong\u003e (from \u003cstrong\u003e$8.4 million\u003c\/strong\u003e) in H1 2025, and cash burn dropped by a further \u003cstrong\u003e19%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eH1 2025\u003c\/td\u003e\n\u003ctd\u003eH1 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Revenues\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Used in Operations\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eThe ability to cut costs by \u003cstrong\u003e74%\u003c\/strong\u003e the prior year and another \u003cstrong\u003e19%\u003c\/strong\u003e in H1 2025 while growing revenue is a rare feat of operational discipline.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet Cash Used in Operating Activities for Full Year 2024 was \u003cstrong\u003e$9.4 million\u003c\/strong\u003e, compared to \u003cstrong\u003e$35.8 million\u003c\/strong\u003e for Full Year 2023, representing a \u003cstrong\u003e74%\u003c\/strong\u003e reduction in cash burn year-over-year.\u003c\/li\u003e\n\u003cli\u003eNet Revenues increased \u003cstrong\u003e59%\u003c\/strong\u003e to \u003cstrong\u003e$4.1 million\u003c\/strong\u003e in H1 2025 from \u003cstrong\u003e$2.6 million\u003c\/strong\u003e in H1 2024.\u003c\/li\u003e\n\u003cli\u003eNet cash used in operations in H1 2025 dropped to \u003cstrong\u003e$5 million\u003c\/strong\u003e from \u003cstrong\u003e$6.2 million\u003c\/strong\u003e in H1 2024, reflecting a further \u003cstrong\u003e19%\u003c\/strong\u003e reduction in cash burn.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eThe specific cuts made are imitable, but the culture of cost-consciousness that allowed this is harder to copy.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSelling, Marketing, and General and Administrative Expenses decreased to \u003cstrong\u003e$5.9 million\u003c\/strong\u003e in H1 2025 from \u003cstrong\u003e$9 million\u003c\/strong\u003e in H1 2024.\u003c\/li\u003e\n\u003cli\u003eResearch and Development Expenses were \u003cstrong\u003e$1 million\u003c\/strong\u003e in H1 2025, compared to \u003cstrong\u003e$0.7 million\u003c\/strong\u003e in H1 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe management team clearly prioritized and executed a massive strategic overhaul to improve financial metrics.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGross profit \u003cstrong\u003edoubled\u003c\/strong\u003e compared to H1 2024.\u003c\/li\u003e\n\u003cli\u003eEnhanced financial stability with up to approximately \u003cstrong\u003e$13.5 million\u003c\/strong\u003e available through At-the-Market ('ATM') and Any Market Purchase agreements as of H1 2025 reporting.\u003c\/li\u003e\n\u003cli\u003eCash balance as of June 30, 2025, was \u003cstrong\u003e$3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary. While impressive, this is a defensive strength; it buys time but doesn't generate new revenue on its own.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eRedHill Biopharma Ltd. (RDHL) - VRIO Analysis: Intellectual Property \u0026amp; Regulatory Momentum\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eIntellectual Property \u0026amp; Regulatory Momentum\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eValue: Protects Talicia and pipeline assets, and the positive FDA feedback on RHB-204 de-risks a major future revenue stream.\u003c\/p\u003e\n\u003cp\u003eRarity: Having a clear, positive regulatory path guidance from the FDA for a novel approach is a significant, though intangible, asset.\u003c\/p\u003e\n\u003cp\u003eImitability: Patents are legally protected, but the momentum from recent regulatory wins is fleeting.\u003c\/p\u003e\n\u003cp\u003eOrganization: The company is clearly organized to push regulatory filings, with the UK MAA for Talicia imminent.\u003c\/p\u003e\n\u003cp\u003eCompetitive Advantage: Sustained. Core IP provides a long-term moat, but the regulatory momentum is temporary until the next approval.\u003c\/p\u003e\n\n\u003cp\u003eThe value derived from the IP and regulatory standing is evidenced by specific exclusivity periods and market potential for key assets.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eKey IP\/Exclusivity Protection End Date (US\/EU)\u003c\/th\u003e\n\u003cth\u003eKey Regulatory Milestone\/Status\u003c\/th\u003e\n\u003cth\u003eEfficacy Data Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTalicia (H. pylori)\u003c\/td\u003e\n\u003ctd\u003eU.S. Patent protection until 2042; 8 years QIDP exclusivity\u003c\/td\u003e\n\u003ctd\u003eFDA Approved November 2019; Leading branded first-line therapy prescribed by U.S. gastroenterologists; UK MAA submission planned for fast-track process, potential approval Q4\/25\u003c\/td\u003e\n\u003ctd\u003eUp to 90% eradication rate (adherent subjects)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRHB-204 (Crohn's Disease)\u003c\/td\u003e\n\u003ctd\u003ePatent protected through 2041 (for pulmonary MAC use); Potential 12 years U.S. exclusivity (QIDP) and 10 years EU exclusivity (Orphan)\u003c\/td\u003e\n\u003ctd\u003eReceived positive FDA feedback on pathway to approval July 21, 2025\u003c\/td\u003e\n\u003ctd\u003eRHB-104 Phase 3 delivered 64% improvement in efficacy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eSpecific financial and operational metrics underscore the current commercial reality and future regulatory trajectory:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTalicia reported U.S. net revenues of $3.0 million in the first half of 2024, increasing to $3.3 million in the first half of 2025.\u003c\/li\u003e\n\u003cli\u003eTotal Net Revenues for RedHill for the first half of 2025 were $4.1 million, up from $2.6 million in the first half of 2024.\u003c\/li\u003e\n\u003cli\u003eTalicia net revenues for the first half of 2025 were $3.8 million.\u003c\/li\u003e\n\u003cli\u003eTotal Talicia net revenues for the full year 2024 were $8.0 million.\u003c\/li\u003e\n\u003cli\u003eThe company received first ex-U.S. Talicia payments totaling $1.1 million following the 2024 launch in the UAE.\u003c\/li\u003e\n\u003cli\u003eThe Crohn's disease market in key territories is projected to grow from $13.6 billion in 2024 to over $19 billion in 2033.\u003c\/li\u003e\n\u003cli\u003eFollowing the co-commercialization joint venture announced October 20, 2025, net Talicia revenues will be shared 50\/50, with Cumberland investing $4.0M.\u003c\/li\u003e\n\u003cli\u003ePost-JV, Talicia has access to approximately 70% commercial and 60% government coverage, stocked at 1,700 CVS pharmacies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eRedHill Biopharma Ltd. (RDHL) - VRIO Analysis: Geographic Expansion\/Ex-U.S. Licensing Framework\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Creates new, non-dilutive revenue streams outside the U.S. commercial focus.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEx-U.S. Talicia revenue from the UAE partnership for H1 2025 was $0.6 million, comprised of $0.5 million in product sales and $0.1 million recognized from royalties.\u003c\/li\u003e\n\u003cli\u003eTotal Net Revenues for H1 2025 were $4.1 million, an increase of 59% from $2.6 million in H1 2024.\u003c\/li\u003e\n\u003cli\u003eTalicia net revenues for H1 2025 totaled $3.8 million.\u003c\/li\u003e\n\u003cli\u003eThe company received its first ex-U.S. Talicia sales milestone and royalties totaling approximately $1.1 million following the first ex-U.S. commercial launch in 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The established framework for securing multiple, smaller ex-U.S. deals is a repeatable skill.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company secured a new Middle East (ME) licensing deal for Talicia, potentially worth up to $1.8 million plus sales royalty payments.\u003c\/li\u003e\n\u003cli\u003eThis new ME deal includes $500,000 in guaranteed payments, consisting of a $250,000 upfront payment and $250,000 in fixed payments due within 18 months.\u003c\/li\u003e\n\u003cli\u003eThe ME deal also includes a minimum of $1.3 million in near-term potential milestone payments.\u003c\/li\u003e\n\u003cli\u003eTalicia is patent protected through 2042 and has eight years of U.S. market exclusivity under its Qualified Infectious Disease Product (QIDP) designation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eNew ME Deal (Potential)\u003c\/th\u003e\n\u003cth\u003eH1 2025 Ex-U.S. Talicia (UAE)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGuaranteed Payments\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$500,000\u003c\/strong\u003e (incl. \u003cstrong\u003e$250,000\u003c\/strong\u003e upfront)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNear-Term Milestones\u003c\/td\u003e\n\u003ctd\u003eMinimum \u003cstrong\u003e$1.3 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Potential Upfront\/Milestone\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$1.8 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalty Structure\u003c\/td\u003e\n\u003ctd\u003eTiered royalties up to \u003cstrong\u003emid-teens percent\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eIncluded in \u003cstrong\u003e$0.1 million\u003c\/strong\u003e royalty revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct Sales Revenue\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Competitors can sign deals, but RedHill Biopharma has demonstrated a specific knack for structuring these smaller, cash-generating partnerships.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTalicia is the #1 branded U.S. gastroenterologist-prescribed H. pylori therapy.\u003c\/li\u003e\n\u003cli\u003eTalicia is the first-line treatment listed in the American College of Gastroenterology (ACG) Clinical Guidelines.\u003c\/li\u003e\n\u003cli\u003eThe company also secured an up to $60 million global (ex-North America) RHB-102 out-licensing deal with Hyloris Pharmaceuticals.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Active discussions are ongoing to secure additional non-dilutive ex-US licensing revenue streams.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company is pursuing potential UK Marketing Authorization Application (MAA) approval for Talicia in 2025.\u003c\/li\u003e\n\u003cli\u003eCash balance as of June 30, 2025, was $3 million.\u003c\/li\u003e\n\u003cli\u003eNet cash used in operations in H1 2025 dropped to $5 million from $6.2 million in H1 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It’s a good strategy, but success depends on finding partners willing to pay in the near term.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company's total assets as of June 30, 2025, were $18.4 million.\u003c\/li\u003e\n\u003cli\u003eThe company has up to approximately $13.5 million available through At-the-Market ('ATM') and Any Market Purchase agreements.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eRedHill Biopharma Ltd. (RDHL) - VRIO Analysis: Enforceable Legal Judgments (Kukbo Win)\u003c\/h2\u003e\n\u003cp\u003eThe New York Supreme Court's summary judgment in favor of RedHill against Kukbo Co. Ltd. is now final and eligible for enforcement and foreign recognition, with no further appeal permissible for the main judgment component.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eJudgment Component\u003c\/td\u003e\n\u003ctd\u003eAmount (Principal + Accrued Interest to Date)\u003c\/td\u003e\n\u003ctd\u003eStatus\u003c\/td\u003e\n\u003ctd\u003eAccruing Interest Rate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMain Judgment\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$8.6 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFinal and Eligible for Enforcement\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e9%\u003c\/strong\u003e Annual Statutory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegal Fees and Expenses Award\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$1.9 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSubject to Appeal until March 13, 2026\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e9%\u003c\/strong\u003e Annual Statutory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Award (Pre-Appeal Resolution)\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e$10.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePartial Final\/Enforceable\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e9%\u003c\/strong\u003e Annual Statutory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eProvides a direct, non-dilutive cash inflow; the main judgment of approximately \u003cstrong\u003e$8.6 million\u003c\/strong\u003e (plus interest) is now final and eligible for enforcement.\u003c\/p\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eWinning a final, enforceable judgment of this size against a former partner is a rare and definitive legal victory.\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eThe legal precedent is set, but replicating the specific circumstances of this dispute is impossible.\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe company successfully pursued and won the appeal, showing commitment to enforcing contractual rights.\u003c\/p\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary. This is a one-time cash boost; once collected, the advantage disappears.\u003c\/p\u003e\n\u003cp\u003eAdditional statistical and financial data points related to the judgment enforcement:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe main judgment of approximately \u003cstrong\u003e$8.6 million\u003c\/strong\u003e is immediately enforceable.\u003c\/li\u003e\n\u003cli\u003eThe legal fees and expenses award of approximately \u003cstrong\u003e$1.9 million\u003c\/strong\u003e remains subject to appeal until \u003cstrong\u003eMarch 13, 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eBoth awards continue to accrue \u003cstrong\u003e9%\u003c\/strong\u003e annual statutory interest.\u003c\/li\u003e\n\u003cli\u003eRedHill has secured a Korean court attachment grant against Kukbo aimed at preventing the disposal of assets prior to judgment enforcement.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eRedHill Biopharma Ltd. (RDHL) - VRIO Analysis: Access to Capital via ATM\/Purchase Agreements\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a financial backstop, with up to approximately $13.5 million available through At-the-Market ('ATM') and Any Market Purchase agreements as of June 30, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Having these agreements in place offers more flexibility than traditional financing, though ATM programs are common.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The specific terms of the agreements with counterparties like Alumni Capital LP are unique.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company actively used the ATM program, raising $3.3 million in net cash from financing activities in H1 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It’s a necessary liquidity tool, but relying on it signals ongoing cash burn challenges.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003ch3\u003eKey Capital Access Metrics (As of H1 2025 \/ June 30, 2025)\u003c\/h3\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvailable Liquidity (ATM\/Purchase Agreements)\u003c\/td\u003e\n\u003ctd\u003eUp to $13.5 million\u003c\/td\u003e\n\u003ctd\u003eAs of June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Provided by Financing Activities\u003c\/td\u003e\n\u003ctd\u003e$3.3 million\u003c\/td\u003e\n\u003ctd\u003eH1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Balance\u003c\/td\u003e\n\u003ctd\u003e$3 million\u003c\/td\u003e\n\u003ctd\u003eAs of June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Used in Operating Activities\u003c\/td\u003e\n\u003ctd\u003e$5 million\u003c\/td\u003e\n\u003ctd\u003eH1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Revenues\u003c\/td\u003e\n\u003ctd\u003e$4.1 million\u003c\/td\u003e\n\u003ctd\u003eH1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eAlumni Capital LP Purchase Agreement Details (Entered June 20, 2025)\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eTotal commitment size: Up to $10,000,000 of American Depositary Shares (ADSs).\u003c\/li\u003e\n\u003cli\u003eADSs sold thus far under the agreement: 1,013,908 ADSs for aggregate net proceeds of approximately $1.7 million.\u003c\/li\u003e\n\u003cli\u003eInitial tranche size: Up to $1,000,000.\u003c\/li\u003e\n\u003cli\u003eInitial tranche pricing: 82% of the lowest daily Volume-Weighted Average Price (VWAP) over the five consecutive trading days prior to the Purchase Notice Date.\u003c\/li\u003e\n\u003cli\u003eForward Purchase Notice pricing: Priced at 96% of the day's lowest traded price.\u003c\/li\u003e\n\u003cli\u003eCommitment Warrants Issued: To purchase 333,333 ADSs at an exercise price of $3.00 per ADS, valid for five years.\u003c\/li\u003e\n\u003cli\u003eOwnership Cap: Generally 4.99% of outstanding ADSs or total issued share capital\/voting rights, increased to 9.99% only for Forward Purchase Notices.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eATM Program Usage (H1 2025)\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eProspectus supplement date: February 3, 2025.\u003c\/li\u003e\n\u003cli\u003eMaximum offering price under supplement: Up to $3,464,000.\u003c\/li\u003e\n\u003cli\u003eADSs sold: 890,001 ADSs.\u003c\/li\u003e\n\u003cli\u003eAverage price per ADS sold: $3.85.\u003c\/li\u003e\n\u003cli\u003eAggregate net proceeds: Approximately $3.3 million.\u003c\/li\u003e\n\u003c\/ul\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516239601813,"sku":"rdhl-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/rdhl-vrio-analysis.png?v=1740210101","url":"https:\/\/dcf-model.com\/fr\/products\/rdhl-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}